BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15232654)

  • 1. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases.
    Kabasakal L; Selçuk NA; Shafipour H; Ozmen O; Onsel C; Uslu I
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1500-4. PubMed ID: 15232654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
    Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
    Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan].
    Rosário PW; Maia FC; Barroso AL; Purisch S
    Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):246-52. PubMed ID: 16184253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
    Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
    Fatourechi V; Hay ID
    Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
    van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
    Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
    Schaap J; Eustatia-Rutten CF; Stokkel M; Links TP; Diamant M; van der Velde EA; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):117-24. PubMed ID: 12100079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
    Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.
    Pacini F; Lippi F; Formica N; Elisei R; Anelli S; Ceccarelli C; Pinchera A
    J Nucl Med; 1987 Dec; 28(12):1888-91. PubMed ID: 3681445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.